ADMA Biologics (NASDAQ:ADMA) Shares Gap Up - Time to Buy?

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $16.31, but opened at $18.29. ADMA Biologics shares last traded at $19.06, with a volume of 3,528,286 shares trading hands.

Analyst Ratings Changes

A number of research firms have commented on ADMA. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $15.50.

ADMA Biologics Stock Up 18.8 %

The firm has a 50 day simple moving average of $17.83 and a two-hundred day simple moving average of $13.27. The stock has a market capitalization of $4.51 billion, a P/E ratio of 142.64 and a beta of 0.62. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same period in the prior year, the company earned ($0.02) EPS. ADMA Biologics's revenue for the quarter was up 78.4% on a year-over-year basis. On average, equities research analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now owns 241,441 shares of the company's stock, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 in the last three months. 3.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $30,000. Principal Financial Group Inc. lifted its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the period. Amalgamated Bank boosted its holdings in ADMA Biologics by 803.0% in the third quarter. Amalgamated Bank now owns 68,169 shares of the biotechnology company's stock valued at $1,363,000 after acquiring an additional 60,620 shares during the last quarter. Roman Butler Fullerton & Co. increased its position in ADMA Biologics by 241.6% during the 3rd quarter. Roman Butler Fullerton & Co. now owns 107,626 shares of the biotechnology company's stock valued at $2,151,000 after purchasing an additional 76,121 shares during the period. Finally, Robeco Institutional Asset Management B.V. raised its holdings in ADMA Biologics by 61.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 179,084 shares of the biotechnology company's stock worth $3,580,000 after purchasing an additional 68,000 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.